CommercialPrior AuthMedium impact
Update to Infliximab Product Coverage
Medical Mutual of Ohio·Rheumatology, Gastroenterology, Dermatology·In the News
Effective date
Jun 1, 2019
We identified it
Jun 20, 2026
Summary
Medical Mutual is implementing a step therapy requirement for infliximab products effective June 1, 2019. New patients must trial two preferred infliximab products (Remicade, Renflexis, Inflectra, Ixifi) before non-preferred products can be prescribed.
Action Required
By June 1, 2019: Providers must ensure new infliximab patients trial preferred products (Remicade, Renflexis, Inflectra, Ixifi) before prescribing non-preferred options. Update treatment protocols and prior authorization processes to document step therapy compliance for Medical Mutual commercial and ACA plans.